Further considering the ability of P2X7 receptor to activate neuroglia, centrally permeable P2X7 receptor antagonists such as JNJ-47965567 [126], Compound 7 [127], and A-438079 [128] should be evaluated for the experimental treatment of neuroinflammatory diseases such as MS. Here, P2RX7 is linked to myeloid sarcoma.